In murine NSCLC models, intratumoral delivery of CXCL9/10-expressing DCs in combination with ICI can overcome resistance to ICI therapy and induce systemic tumor-specific immunity, primarily through CXCR3-mediated recruitment of intratumoral CD4+ and CD8+T cells (117). This evidence concerns the gene CD8A and non-small cell lung carcinoma.